IFP Advisors Inc Has $52,000 Position in Evolus, Inc. (NASDAQ:EOLS)

IFP Advisors Inc increased its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 17,440.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,736 shares of the company’s stock after purchasing an additional 4,709 shares during the quarter. IFP Advisors Inc’s holdings in Evolus were worth $52,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Barclays PLC boosted its holdings in shares of Evolus by 268.0% during the third quarter. Barclays PLC now owns 93,662 shares of the company’s stock worth $1,518,000 after purchasing an additional 68,213 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in Evolus by 173.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after acquiring an additional 265,635 shares during the last quarter. Jane Street Group LLC lifted its stake in Evolus by 47.0% in the third quarter. Jane Street Group LLC now owns 91,899 shares of the company’s stock valued at $1,489,000 after acquiring an additional 29,396 shares during the last quarter. Lord Abbett & CO. LLC lifted its stake in Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after acquiring an additional 188,685 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Evolus by 63.5% in the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company’s stock valued at $2,753,000 after acquiring an additional 65,972 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus Price Performance

Shares of Evolus stock opened at $13.50 on Friday. The firm has a fifty day simple moving average of $12.85 and a 200-day simple moving average of $14.08. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The stock has a market capitalization of $854.83 million, a price-to-earnings ratio of -14.84 and a beta of 1.33.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Wednesday.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.